Wedbush Downgrades Fate Therapeutics (FATE) to Neutral

February 26, 2021 6:14 AM EST
Get Alerts FATE Hot Sheet
Price: $84.28 -2.05%

Rating Summary:
    15 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 11 | New: 8
Trade Now! 
Join SI Premium – FREE

Wedbush analyst David Nierengarten downgraded Fate Therapeutics (NASDAQ: FATE) from Outperform to Neutral with a price target of $88.00.


For an analyst ratings summary and ratings history on Fate Therapeutics click here. For more ratings news on Fate Therapeutics click here.


Shares of Fate Therapeutics closed at $86.27 yesterday.


You May Also Be Interested In





Related Categories

Downgrades